Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 23, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Appoints Dr. Rand Sutherland as President
March 22, 2021 07:30 ET
|
Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
March 17, 2021 16:05 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
March 12, 2021 01:00 ET
|
Translate Bio, Inc.
-- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 03, 2021 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress
February 25, 2021 16:05 ET
|
Translate Bio, Inc.
-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Two infectious disease mRNA vaccine programs expected to enter...
Translate Bio to Present at the SVB Leerink Virtual 10th Annual Global Healthcare Conference
February 18, 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 03, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
January 07, 2021 07:30 ET
|
Translate Bio, Inc.
-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...
Translate Bio Announces Departure of Chief Financial Officer
December 22, 2020 16:20 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...